These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

432 related items for PubMed ID: 19915352

  • 1. [Development of thrombopoietin receptor agonists].
    Miyakawa Y.
    Rinsho Ketsueki; 2009 Oct; 50(10):1434-43. PubMed ID: 19915352
    [No Abstract] [Full Text] [Related]

  • 2. Venous thromboembolism and coagulation activity in patients with immune thrombocytopenia treated with thrombopoietin receptor agonists.
    Ghanima W, Lee SY, Barsam S, Miller A, Sandset PM, Bussel JB.
    Br J Haematol; 2012 Sep; 158(6):811-4. PubMed ID: 22816787
    [No Abstract] [Full Text] [Related]

  • 3. [Management of refractory ITP with thrombopoietin receptor agonists].
    Tomiyama Y.
    Rinsho Ketsueki; 2011 Aug; 52(8):627-32. PubMed ID: 21897068
    [No Abstract] [Full Text] [Related]

  • 4. Safety and efficacy of romiplostim in patients with eltrombopag-resistant or -intolerant immune thrombocytopenia.
    Tsukamoto S, Nakaseko C, Takeuchi M, Kumagai K, Komatsu T, Tanaka H, Hara S, Koizumi M, Imai H, Yokota A, Takeuchi M, Inokuchi K, Matsuura Y, Aotsuka N, Wakita H.
    Br J Haematol; 2013 Oct; 163(2):286-9. PubMed ID: 23862773
    [No Abstract] [Full Text] [Related]

  • 5. Effectiveness of thrombopoietin-receptor agonists in the treatment of refractory immune thrombocytopenia associated to systemic lupus erythematosus.
    Magnano L, Enríquez H, Esteve J, Cervera R, Espinosa G.
    J Rheumatol; 2014 Sep; 41(9):1895-6. PubMed ID: 25179983
    [No Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. Thrombopoietin receptor agonists in immune thrombocytopenia of less than 6 months duration.
    Arumugaswamy A, He S, Quach H, Brotchie J, Grigg A.
    Intern Med J; 2014 May; 44(5):519-21. PubMed ID: 24816314
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. Infection-related transient loss of response and other early side effects in chronic ITP during treatment with thrombopoietin mimetics.
    Meyer O, Salama A.
    Onkologie; 2011 May; 34(1-2):10-3. PubMed ID: 21346379
    [Abstract] [Full Text] [Related]

  • 14. Thrombopoietin Receptor Agonist Use for Immune Thrombocytopaenia.
    Neunert CE.
    Hamostaseologie; 2019 Aug; 39(3):272-278. PubMed ID: 30646404
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. Sustaining platelet counts in chronic ITP.
    Nurden AT.
    Lancet; 2011 Jan 29; 377(9763):358-60. PubMed ID: 20739056
    [No Abstract] [Full Text] [Related]

  • 17. A decision framework for treating chronic immune thrombocytopenia with thrombopoietin receptor agonists.
    Dolph M, Roy A, Bhor M, Hearnden J, Kwon CS, Forsythe A, Tremblay G, Briggs A.
    J Comp Eff Res; 2018 Aug 29; 7(8):775-784. PubMed ID: 29848048
    [Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 22.